Company: INMB
Filing Date: 2025-06-30
Form Type: 424B5
Source: 0001213900-25-059298
Chunk: 8

Company: Inmune Bio, Inc.
Filing Date: 2025-06-30
Form: 424B5
Chunk 8
---
 of our common stock sold subsequent to March 31, 2025 pursuant to our “at-the-market” sales agreement with RBC Capital Markets LLC and BTIG, LLC, at a weighted average price of $7.42 per share |

Unless we specifically state otherwise, all information in this prospectus supplement assumes no exercise of the potential issuance of shares of our common stock that remain available for sale as of the date of this prospectus supplement under our Sales Agreement.

<div align='center'>S-3

RISK FACTORS</div>

An investment in our common stock involves a high degree of risk. Prior to making a decision about investing in our common stock, you should carefully consider the risk factors described below and the risk factors discussed in the sections entitled “Risk Factors” contained in our most recent Annual Report on Form 10-K, and our other filings with the SEC and incorporated by reference in this prospectus supplement, together with all of the other information contained in this prospectus supplement. Our business, financial condition and results of operations could be materially and adversely affected as a result of these risks. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment.

Risks Related to this Offering

You may experience immediate and substantial dilution as a result of this offering and may experience additional dilution in the future.

You may incur immediate and
substantial dilution as a result of this offering. After giving effect to the sale by us of up to 3,000,000 shares offered in this offering
at a public offering price of $6.30 per share, and after deducting Placement Agent fees and offering expenses payable by us, investors
in this offering can expect an immediate pro forma dilution of $4.97 per share. We have a significant number of stock options and warrants
outstanding, and, in order to raise additional capital, we may in the future offer additional shares of our common stock or other securities
convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. In the
event that the outstanding options and/or warrants are exercised, or that we make additional issuances of common stock or other convertible
or exchangeable securities, you could experience additional dilution. We cannot assure you that we will be able to sell shares or other
securities in any other offering at a price per share that is equal to or greater than the price per share paid by